| Drug General Information |
| Drug ID |
D0F9KL
|
| Former ID |
DAP001503
|
| Drug Name |
PD-172760
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Approved |
[1]
|
|---|
| Company |
AstraZeneca
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H25N3O2S
|
| Canonical SMILES |
C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
|
| InChI |
1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
|
| InChIKey |
URKOMYMAXPYINW-UHFFFAOYSA-N
|
| CAS Number |
CAS 111974-69-7
|
| PubChem Compound ID |
|
| PubChem Substance ID |
9601, 631813, 5198881, 7980444, 8153080, 14756073, 26612817, 26749928, 29215183, 29215184, 29224074, 46504800, 48416505, 49666155, 49666758, 50064167, 50606342, 56312011, 56312821, 56394834, 57288825, 61127934, 85209878, 92308036, 93166437, 93619787, 96025142, 103195252, 103993497, 104307995, 108136177, 114919760, 124799953, 125337908, 126525318, 126653074, 126671681, 127275837, 127275838, 127275839, 127275840, 127275841, 127275842, 127275843, 129409886, 134337331, 134338691, 134339382, 134358152, 135017541
|
| ChEBI ID |
ChEBI:8707
|
| SuperDrug ATC ID |
N05AH04
|
| SuperDrug CAS ID |
cas=111974697
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Antagonist |
[1]
|
|---|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. |
|---|
